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Background: The aim of this study was to evaluate the clinical efficacy of submandibular gland transfer for the
prevention of xerostomia after radiotherapy for nasopharyngeal carcinoma.
Methods: Using the randomized controlled clinical research method, 65 patients with nasopharyngeal carcinoma
were randomly divided into an experimental group consisting of 32 patients and a control group consisting of 33
patients. The submandibular glands were averted to the submental region in 32 patients with nasopharyngeal
carcinoma before they received conventional radiotherapy; a lead block was used to shield the submental region
during therapy. Prior to radiotherapy, the function of the submandibular glands was assessed using imaging.
Submandibular gland function was measured using 99mTc radionuclide scanning at 60 months after radiotherapy.
The data in the questionnaire regarding the degree of xerostomia were investigated and saliva secretion was
measured at 3, 6, 12, and 60 months after radiotherapy. In addition, the 5-year survival rate was calculated.
Results: After follow-up for 3, 6, and 12 months, the incidence of moderate to severe xerostomia was significantly
lower in the experimental group than in the control group. The average amount of saliva produced by the
experimental and control groups was 1.60 g and 0.68 g, respectively (P < 0.001). After follow-up for 60 months, the
uptake and secretion functions of the submandibular glands in the experimental group were found to be
significantly higher than in the control group (P < 0.001 and P < 0.001, respectively). The incidence of moderate or
severe xerostomia was significantly lower than in the control group (15.4% and 76.9%, respectively; P < 0.001). The
5-year survival rates of the experimental group and the control group were 81.3% and 78.8%, respectively, and there
was no significant difference between the two groups (P = 0.806).
Conclusions: After a 5 year follow-up period involving 32 patients who had their submandibular glands transferred
for the prevention of xerostomia after radiotherapy for nasopharyngeal carcinoma, we found that clinical efficacy
was good. This approach could improve the quality of life of nasopharyngeal carcinoma patients after radiotherapy
and would not affect long-term treatment efficacy.
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Median age 45.6 47.8
Males 25 24
Females 7 9






Radiotherapy alone 18 17
Concurrent chemoradiotherapy 14 16
Zhang et al. Radiation Oncology 2014, 9:62 Page 2 of 8
http://www.ro-journal.com/content/9/1/62Background
Nasopharyngeal carcinoma (NPC) is a common malig-
nancy in the southeast provinces of China. Currently,
concurrent radiochemotherapy is a mainstay of curative
treatment for NPC. Xerostomia is a frequent and rele-
vant side effect for NPC patients after radiation therapy
(RT). Xerostomia, although not life-threatening on its
own, affects patients’ quality of life because it causes ser-
ious disorders in tasting, chewing, and swallowing, as
well as sleeping disorders. After RT, xerostomia can be
treated with fluoride, pilocarpine, and some other drugs,
but their efficacy is unsatisfactory [1]. Prevention of
radiation-induced xerostomia can be achieved by chan-
ging the dose-time-splits to improve the biological
effects of treatments, such as appropriate RT, intensity-
modulated RT and RT plus protective agent [2,3]; how-
ever, most patients will not benefit because of the extra
expense entailed in doing this.
In an effort to prevent radiation-induced xerostomia
for patients with head and neck squamous cell carcin-
oma, Jha and Seiklay [4-6] first reported on the transfer
of the submandibular gland to the submental space,
which is an area that can be shielded from radiation
without detrimental effects on cure rates in tumors dis-
tant from the submental triangle; this approach achieved
good results. In a prospective randomized phase III clin-
ical trial, a new way of preventing radiation-induced xer-
ostomia was demonstrated, namely submandibular gland
transfer; this was significantly more effective than oral
pilocarpine [6]. Based on findings from animal experi-
ments, we transferred the submandibular glands of 32
NPC patients before conventional RT to prevent xeros-
tomia. After a follow-up period of 5 years, it was clear
that we had achieved good preventative effects.
Methods
Ethics statement
The Ethical Committee of the Tumor Hospital of Ganzhou
Review Board approved the study protocol (20040311),
and the study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki regarding research in-
volving human subjects. Each of the patients provided
written informed consent to participate after the nature of
the study had been explained to them.
Inclusion and exclusion criteria
Inclusion criteria
The inclusion criteria were as follows: (1) Patients aged
20–60 years. (2) Patients who had undergone a nasopha-
ryngeal biopsy for the diagnosis of undifferentiated naso-
pharyngeal non-keratinizing carcinoma. (3) Patients with
no cervical lymph node metastasis or unilateral cervical
lymph node metastasis. (4) Patients who had undergone
conventional RT. (5) A Karnofsky performance score ≥ 80.(6) Life expectancy of at least 1 year. (7) Patients who under-
stood and voluntarily signed an informed consent form.
Exclusion criteria
The exclusion criteria were as follows: (1) Bilateral cer-
vical lymph node metastasis. (2) Bilateral district cervical
lymph node metastasis. (3) Submandibular gland dis-
eases. (4) A history of neck surgery or RT. (5) Distant
metastasis. (6) Patients in poor general condition who
could not tolerate surgery.
Clinical data
This was a prospective clinical randomized controlled
study. A total of 65 patients with NPC, from March
2004 to August 2006, were randomly divided into two
groups; the experimental group consisted of 32 patients
and the control group consisted of 33 patients. There
were no significant differences between the two groups
concerning the general information (Table 1). Before RT,
the 32 patients in the experimental group underwent
unilateral submandibular gland transfer. For those pa-
tients with unilateral cervical lymph node metastasis, the
contralateral submandibular gland was transferred. For
patients with no lymph node metastasis, the contralat-
eral submandibular gland transfer was carried out ac-
cording to tumor location in the nasopharynx.
Preoperative examination
In addition to a special inspection of the nasopharyngeal
carcinoma, the head and neck were examined to check
the wetness of the oral mucosa, the saliva pool of the
mouth floor, and bilateral submandibular duct saliva se-
cretion in the mouth. Patients in whom an impairment
of submandibular gland function was expected were ex-
cluded from the study.
Figure 2 Photograph showing dissected adipose tissue.
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Surgery was carried out under local or general anesthesia.
The following procedures were performed: (1) A 2 cm
long submandibular parallel incision, a skin incision, and
subcutaneous separation of a platysma flap (up and down)
extending to the horizontal branch of the mandible and
hyoid were undertaken; the submandibular gland was ex-
posed (Figure 1). (2) Specimens obtained from the explor-
ation of Zone I and Zone I lymph node adipose tissue
dissection were quickly frozen and sectioned; evaluation
confirmed that no cancer cell metastasis was present
(Figure 2). (3) Release of the lower edge of the subman-
dibular gland was accomplished by the following proced-
ure: separation of the digastric belly; location of the facial
artery and vein on the edge of the deep surface and their
cutoff after double legation; freeing of the posterior pole
of the submandibular gland while retaining the facial ar-
tery, vein, submandibular ganglion, and the marginal man-
dible branch of the facial nerve; loosening the edge of the
submandibular gland; and freeing the anterior belly of the
digastric cutoff region of the mylohyoid muscle (Figure 3).
(4) The external maxillary artery, vein, and submandibular
duct functioned as a pedicle, and the submandibular gland
was released and transferred to the submental area of the
anterior belly of the digastric deep surface; this was fixed
with silver clips around the gland that acted as RT
markers (Figure 4). For the use of these clinical materials
for research purposes, prior patient's consent and approval
from the Ganzhou Institute of Cancer Research Ethics
Committee (20040311) were obtained.Radiation treatment
RT was administered to the experimental and control
groups using a Siemens linear accelerator that generated 6
MV X-rays. The position of the center of the irradiationFigure 1 Photograph showing a 2 cm parallel incision that has
exposed the submandibular gland.field was unchanged, fixed thermal plastic masks were
used, and a low-melting lead shield was employed to spe-
cifically block the exposure to radiation by tissues outside
of the irradiation field. Conventional fractionated RT was
delivered in 2 Gy fractions, once daily, and 5 times per
week; the nasopharynx target therapeutic dose was 65–
75 Gy, the cervical lymph node metastases therapeutic
dose was 60–70 Gy, and the cervical lymph node prevent-
ive dose was 45–50 Gy (Figures 5, 6 and 7).Observed indicators
Postoperative observation
Observation included wound healing after surgery, the
occurrence of complications, and submental and sub-
mandibular lymph node pathology.Figure 3 Photograph showing frozen submandibular gland and
the anterior belly of the digastric.
Figure 4 Photograph showing the submandibular gland fixed
in position with silver clips that were also used as markers.
Figure 6 X-ray showing the delineation of the auriculotemporal
field in the facial and cervical regions after 19 fractions of
radiotherapy (38 Gy); the transferred submandibular gland is
outside of the irradiation field.
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Imaging of the submandibular gland was performed at
2 weeks after RT in the experimental group; submandibu-
lar gland 99 mTc radionuclide imaging was also performed
at 60 months after RT. Imaging of the submandibular
gland was performed at 3 days before RT in the control
group; submandibular gland 99 mTc radionuclide imaging
was also performed at 60 months after RT.
Determination of saliva secretion
Saliva secretion was measured in the experimental and
control groups at 3, 6, 12, and 60 months after RT.Figure 5 X-ray showing the simulation of the facial and cervical
joint field positioning. The transferred submandibular is outside
of the irradiation field.
Figure 7 X-ray showing the delineation of the whole neck
tangential field in the facial and cervical regions after 19 fractions
of radiotherapy (38 Gy); the transferred submandibular gland
is shielded.
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against the hard palate, then a number of dry cotton
balls were placed in their sublingual mound openings.
About 10 minutes later, the wet cotton balls containing
saliva were removed and weighed. To reduce physio-
logical interference, determination of saliva secretion
was conducted at 1 hour after eating. The amount of sal-
iva secreted was determined as follows: saliva weight (g) =
wet cotton ball weight - dry cotton ball weight.Xerostomia questionnaire
In the experimental and control groups, a questionnaire
regarding the degree of xerostomia was completed by
the patients at 3, 6, 12, and 60 months after RT, and
evaluated using the visual analysis scale (VAS) method
[7], and by evaluation of subjective symptoms [8]. Xeros-
tomia evaluation criteria refer to the RTOG/EORTC [9]
RT staging criteria.Neck lymph node residual rate, recurrence, and survival
At 3 months after RT, the cervical lymph node residual
rate, the neck lymph node recurrence site, the cervical
lymph node recurrence rate, and the 5-year survival
rates were evaluated in the two patient groups.Statistical methods
The SPSS 14.0 statistical package was used for process-
ing data. The 5-year survival rate was calculated using
the Kaplan-Meier method, and the difference between
the groups was compared using the log-rank parallel
test. The xerostomia survey data and the submandibular
gland radionuclide scintigraphy data for patients at
60 months after RT were compared using the two sam-
ple data non-parametric test. Differences in saliva secre-
tion, dry mouth, and the VAS scoring results between
the two groups were evaluated using the two independ-
ent sample data t tests. Survey data, the incidence of se-
vere xerostomia, and the cervical lymph node recurrence
rate were compared using the χ2 test. A P value of <0.05
was considered statistically significant.Table 2 Survey results regarding the degree of xerostomia








None (G1) 7 (21.9%) 0 (0.0%) 4.428 0.000
Mild (G2) 13 (40.6%) 2 (6.1%)
Moderate (G3) 8 (25.0%) 18 (54.5%)
Severe (G4) 4 (12.5%) 13 (39.4%)Results
Postoperative observation
The submandibular glands of 32 patients were trans-
ferred successfully, and no surgery related deaths or
complications occurred. All incisions healed well and pa-
tient chins were slightly plump after the removal of
stitches. A total of 107 lymph nodes were scavenged;
metastasis was not found in the intraoperative rapidly
frozen or paraffin sections. During the follow-up period,
no patients complained of obvious discomfort caused by
the surgery.Examination of submandibular gland function
Before RT, the submandibular gland secretion function
was normal, as confirmed using imaging in the two pa-
tient groups; there was no significant difference between
the two groups (P = 0.675). At 60 months after RT, all of
the patients underwent submandibular gland radio-
nuclide scintigraphy; submandibular gland uptake and
secretion were significantly higher in the experimental
group than in the control group (P < 0.001).
Comparison of saliva flow measurement results
At 3, 6, 12, and 60 months after RT, the average amount
of saliva was 1.19 g, 1.28 g, 1.39 g, and 1.60 g, respectively
in the experimental group. The average amount of saliva
in the control group at 3, 6, 12, and 60 months after RT
was 0.58 g, 0.63 g, 0.66 g, and 0.68 g, respectively.
Evaluation of xerostomia at 3, 6, and 12 months after RT
The incidence of xerostomia in the experimental group
at 3 months after RT ranged from moderate to severe,
and it was significantly lower than in the control group
(37.4% and 93.9%, respectively; P < 0.001). The incidence
of xerostomia in the experimental group at 6 months
after RT ranged from moderate to severe, and it was sig-
nificantly lower than in the control group (28.1% and
87.9%, respectively; P < 0.001). The incidence of xerosto-
mia in the experimental group at 12 months after RT
ranged from moderate to severe, and it was significantly
lower than in the control group (18.7% and 81.8%, re-
spectively; P < 0.001). Thus, at 3, 6, and 12 months after
RT, the average xerostomia level in the experimental
group was significantly lower than in the control group
(Tables 2, 3 and 4). With increasing time after RT, the
symptoms of xerostomia progressively improved.
Evaluation of xerostomia at 60 months after RT
The survey results regarding xerostomia are detailed in
Table 5. The incidence of xerostomia in the experimen-
tal group ranged from moderate to severe and was sig-
nificantly lower than in the control group (15.4% and
76.9%, respectively; P < 0.001). The estimated VAS score
results based on the patients’ own subjective feelings re-
garding xerostomia were as follows: the VAS score in the
experimental group (3.7) was lower than in the control
Table 3 Survey results regarding the degree of xerostomia








None (G1) 8 (25.0%) 0 (0.0%) 4.584 0.000
Mild (G2) 15 (46.9%) 4 (12.1%)
Moderate (G3) 6 (18.7%) 19 (57.6%)
Severe (G4) 3 (9.4%) 10 (30.3%)
Table 5 Survey results regarding the degree of xerostomia








None (G1) 7 (26.9%) 0 (0.0%) 4.423 0.000
Mild (G2) 15 (57.7%) 6 (23.1%)
Moderate (G3) 3 (11.5%) 16 (61.5%)
Severe (G4) 1 (3.9%) 4 (15.4%)







Day xerostomia 16 (61.5%) 26 (100%) 0.000
Night xerostomia 4 (15.4%) 20 (76.9%) 0.000
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tween the two groups (P < 0.001). Some of the important
issues concerning the survey results and the degree of
subjective feelings regarding the symptoms of xerosto-
mia are presented in Table 6. In the experimental group,
speech, chewing, swallowing, changes in eating habits,
nighttime xerostomia, the need to wake up to drink fre-
quently, and sleep quality were all improved significantly
relative to the control group.
Cervical lymph node residual rate, cervical lymph node
recurrence rate, and 5-year survival rate
The experimental and control groups had no cervical
lymph node residues at 3 months after RT. The cervical
lymph node recurrence rates in the experimental and
control groups were 15.6% (5/32) and 12.1% (4/33), re-
spectively; there was no significant difference (P = 0.960)
between the two groups. Lymph node recurrence oc-
curred exclusively in Zone II and was not evident in
Zone I. In the experimental and control groups, the 5-
year survival rates were 81.3% (26/32) and 78.8% (26/
33), respectively; there was no significant difference be-
tween the two groups (P = 0.806).
Follow-up
The follow-up period began at the end of RT and contin-
ued until December 31, 2011. A total of 65 patients were
followed up for 28–60 months.
Discussion
The submandibular gland is a mixed gland, containing
both serous and mucous cells. Approximately 90% of
total saliva is produced by the submandibular gland in
non-stimulated conditions. The total daily flow of salivaTable 4 Survey results regarding the degree of xerostomia





Control group Z-value P-value
None (G1) 8 (25.0%) 0 (0.0%) 4.896 0.000
Mild (G2) 18 (56.3%) 6 (18.2%)
Moderate (G3) 4 (12.5%) 19 (57.%)
Severe (G4) 2 (6.2%) 8 (24.2%)from the submandibular gland is around 200–300 ml. A
considerable proportion of the saliva is mucus; this con-
tributes to the sensation of oral comfort as a result of
the continuous lubrication of the oral mucosa. Saliva
also lubricates the mouth during periods of non-eating,
and reduces the symptoms of xerostomia [10-13].
Three major salivary glands are located in the radi-
ation field when NPC patients receive conventional RT,
and radiation damage to these glands is permanent. The
basic feature of submandibular gland transfer for the
prevention of xerostomia is the transfer of the subman-
dibular gland to the submental area. A stopper is set in
the submental area, and only approximately 5% of the
total radiation dose (30–32.5 Gy) is received by the sub-
mandibular gland; thus, the submandibular gland re-
mains free from damage [14]. Therefore, to preserve
submandibular gland function, patients with serious
damage and lymph node metastasis in region I were not
suitable for surgery. In addition, patients who had
undergone previous neck surgery and had a history of
RT were not suitable for surgery. In the group of 32 pa-
tients that received intraoperative cleaning of the 107
lymph nodes, observation of intraoperative rapidly fro-
zen slices and postoperative paraffin biopsy did not
reveal metastasis. Consequently, the prerequisite for sub-
mandibular gland transfer in patients with NPC was the
absence of neck Zone I lymph node metastasis. In thePainful mouth and tongue 6 (23.1%) 9 (34.6%) 0.358
Dry, cracking and painful lips 5 (19.2%) 7 (26.9%) 0.510
Regular drinking during the day 17 (65.4%) 26 (100%) 0.003
Regular drinking during the night 1 (3.9%) 4 (15.4%) 0.347
Drinking when eating 4 (15.4%) 20 (76.9%) 0.000
Difficulty speaking 2 (7.7%) 14 (53.8%) 0.000
Difficulty chewing 3 (11.5%) 17 (65.4%) 0.000
Difficulty swallowing 1 (3.8%) 5 (19.2%) 0.193
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submandibular gland with no lymph node metastasis
was transferred. If there was no lymph node metastasis,
the contralateral submandibular gland was transferred.
The key success regarding submandibular gland trans-
fer surgery for the prevention of RT xerostomia lies in
patient survival and the sustainability of saliva secretion.
In our study, at 60 months after RT, the xerostomia sur-
vey results indicated that 26 patients in the control
group had varying degrees of xerostomia, with 76.9% of
the patients suffering from moderate to severe dry
mouth; these results are similar to those reported in the
literature [15]. At 3 months after RT, the incidence of
xerostomia in the experimental group ranged from mod-
erate to severe and was significantly lower than in the
control group; with increasing time after RT, their symp-
toms improved. In the experimental group at 60 months
after RT, the average quantity of saliva secretion,
checked using submandibular gland radionuclide scintig-
raphy, was obviously higher than in the control group;
there were significant differences between the two
groups. In the experimental group, the incidence of
moderate to severe xerostomia, standard of speech,
chewing ability, swallowing ability, changes in eating
habits, nighttime xerostomia, need to wake up and drink
frequently, sleep quality, and VAS scores were signifi-
cantly improved relative to the control group. As a result
of transfer after RT, the submandibular gland not only
survived but also retained a strong secretion function.
Thus, submandibular gland transfer was an effective
method for preventing xerostomia after RT.
In NPC patients at 3 months after RT, the experimen-
tal group and the control group had no residual lymph
nodes, and submandibular gland transfer did not affect
the cervical lymph node control rate. There was no sig-
nificant difference between the experimental and control
groups regarding the cervical lymph node recurrence
rate. Recurrence occurred in Region II but not in Region
I. Therefore, submandibular gland transfer did not affect
the recurrence rate in the cervical lymph node. There
was no significant difference in the 5-year survival rate
between the two patient groups and submandibular
gland transfer did not affect the 5-year survival rate.
Thus, submandibular gland transfer had no effect on the
long-term efficacy of NPC treatment using RT. These re-
sults are consistent with those of Seikaly et al. [16].
These authors reported that when the submandibular
gland was transferred to the submental area of the oro-
pharynx, larynx, and hypopharynx during the treatment
of malignant tumors using RT, xerostomia did not influ-
ence the survival rate or recurrence rate in the lymph
nodes of the neck.
Because the transferred submandibular gland could
survive after RT, it retained a strong secretory functionand could effectively prevent xerostomia after RT. How-
ever, submandibular gland transfer could not fully solve
the problem of xerostomia because mild and severe xer-
ostomia still occurred. After 5 years, xerostomia still had
an occurrence rate of 15.4%. A number of studies [17-19]
have shown that when using intensity-modulated RT tech-
niques, the radiation dose delivered to the parotid gland
and high-dose irradiation volume can be reduced to pro-
tect the functions of the parotid gland. This approach
could reduce the degree of xerostomia after RT in NPC
patients. Consequently, whether submandibular gland
transfer and intensity-modulated RT should be adopted
for the protection of the submandibular gland and the
prevention of xerostomia after RT in the treatment of
NPC requires evaluation in further clinical studies.
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